Credit Suisse analyst, Martin Auster, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) ahead of the initial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE